immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product can50 didates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In September 2006 â€“ and thus less than three years after the conclusion of the first round of funding totaling â‚¬14 million â€“ the company successfully concluded an international clinical study on its product candidate IMA901 for combating renal cancer. Further product candidates, also consisting of peptide-based immuno55 therapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.
Funding Rounds (5) - $176.5MUpdate
AT Impf was added to CrunchBase in 2010
Wellington Partners is a venture capital firm that invests in technology and life sciences...
MIG-advised funds was added to CrunchBase in 2010
OH Beteiligungen was added to CrunchBase in 2010
National Technology Enterprises Company
KfW Bankengruppe gives impetus to economic, social and ecological development worldwide. As a...
3i is a British private equity group that has billions under management. For over 65 years...
- 07/16/14 -prnewswire.com